Methods and Crosslinked Polymer Compositions for Cartilage Repair

1 - 217 . (canceled)

218 . A method of repairing damaged cartilage tissue in a patient comprising placing into contact with the damaged cartilage tissue a composition comprising components (i), (ii), and (iii) or a partial reaction product of components (i), (ii), and (iii), wherein components (i), (ii), and (iii) are comprised of:

(i) a first hydrophilic polymer;

(ii) a crosslinkable component A having m nucleophilic groups, wherein m≧2; and

(iii) a crosslinkable component B having n electrophilic groups capable of reaction with the m nucleophilic groups to form covalent bonds, wherein n≧2 and m+n>4,

wherein each of components A and B is biocompatible and nonimmunogenic, at least one of components A and B is a second hydrophilic polymer, and reaction of components (i), (ii), and (iii) results in a biocompatible, nonimmunogenic, crosslinked matrix.

219 . The method of claim 218 , wherein the damaged cartilage tissue is selected from the group consisting of articular cartilage tissue, a meniscus, or labrum.

220 . The method of claim 218 , wherein the first hydrophilic polymer is selected from a synthetic hydrophilic polymer and a naturally occurring hydrophilic polymer.

221 . The method of claim 220 , wherein the naturally occurring hydrophilic polymer is selected from the group consisting of proteins, peptides, polysaccharides, lipids and derivatives thereof.

222 . The method of claim 221 , wherein the protein is a collagen.

223 . The method of claim 222 , wherein the collagen is selected from the group consisting of nonfibrillar collagen, fibrillar collagen, and a mixture of nonfibrillar collagen and fibrillar collagen.

224 . The method of claim 223 , wherein the nonfibrillar collagen is selected from the group consisting of methylated collagen, type IV collagen, type VI collagen, and type VII collagen.

225 . The method of claim 218 , wherein the second hydrophilic polymer is selected from the group consisting of polyalkeleneoxides, polyurethanes, polyesters, polyethers, polythioethers, polyamides, and derivatives, copolymers, and combinations thereof.

226 . The method of claim 218 , wherein components A and B each comprise a polyalkyleneoxide.

227 . The method of claim 226 , wherein the polyalkyleneoxide is a poly(ethylene glycol).

228 . The method of claim 218 , wherein components A and B are the same.

229 . The method of claim 218 , wherein components A and B are in admixture.

230 . The method of claim 229 , wherein the admixture is in a solid form.

231 . The method of claim 218 , wherein component A has the structural formula (I) and component B has the structural formula (II)

R 1 (-[Q 1 ] q -X) m   (I)

R 2 (-[Q 2 ] r -Y) n   (II)

wherein:

R 1 and R 2 are independently selected from the group consisting of C 2 to C 14 hydrocarbyl, heteroatom-containing C 2 to C 14 hydrocarbyl, hydrophilic polymers, and hydrophobic polymers;

X represents one of the m nucleophilic groups of component A;

Y represents one of the n electrophilic groups of component B;

Q 1 and Q 2 are linking groups; and

q and r are independently zero or 1.

232 . The method of claim 231 , wherein at least one of R 1 and R 2 is a synthetic hydrophilic polymer.

233 . The method of claim 218 , wherein the composition further comprises a third crosslinkable component C that is biocompatible and nonimmunogenic and has at least one functional group selected from

(a) nucleophilic groups capable of reacting with the electrophilic groups of component B and,

(b) electrophilic groups capable of reacting with the nucleophilic groups of component A,

wherein the total number of functional groups on component C is represented by p, such that m+n+p>5.

234 . The method of claim 233 , wherein component C has the structural formula (III)

R 3 (-[Q 3 ] s Fn) p   (III)

wherein:

R 3 is selected from the group consisting of C 2 to C 14 hydrocarbyl, heteroatom-containing C 2 to C 14 hydrocarbyl, hydrophilic polymers, and hydrophobic polymers;

Fn represents a functional group on component C; and

s is zero or 1.

235 . The method of claim 232 , wherein the synthetic hydrophilic polymer is selected from the group consisting of: polyalkylene oxides; polyglycerols; poly(oxyalkylene)-substituted polyols; polyacrylic acid and analogues thereof; polymaleic acid; polyacrylamides; poly(olefinic alcohol)s; poly(N-vinyl lactams); polyoxazolines; polyvinylamines; and copolymers thereof.

236 . The method of claim 235 , wherein the synthetic hydrophilic polymer is a polyalkylene oxide selected from the group consisting of polyethylene glycol and poly(ethylene oxide)-poly(propylene oxide) copolymers.

237 . The method of claim 218 , wherein the nucleophilic groups on component A are selected from the group consisting of —NH 2 , —NHR 4 , —N(R 4 ) 2 , —SH, —OH, —COOH, —C 6 H 4 —OH, —PH 2 , —PHR 5 , —P(R 5 ) 2 , —NH—NH 2 , —CO—NH—NH 2 , and —C 5 H 4 N, wherein R 4 and R 5 are C 1 -C 12 hydrocarbyl.

238 . The method of claim 237 , wherein the nucleophilic groups are selected from —NH 2 and —NHR 4 where R 4 is lower hydrocarbyl.

239 . The method of claim 238 , wherein the electrophilic groups on component B are amino-reactive groups.

240 . The method of claim 237 , wherein the amino-reactive groups contain an electrophilically reactive carbonyl group susceptible to nucleophilic attack by a primary or secondary amine.

241 . The method of claim 237 , wherein the amino-reactive groups are selected from the group consisting of carboxylic acids, carboxylic acid esters, and aldehydes.

242 . The method of claim 218 , wherein the composition further comprises a biologically active agent that facilitates tissue healing and regeneration.

243 . The method of claim 242 , wherein the biologically active agent is selected from the group consisting of an angiogenesis inhibitor, paclitaxel, enzymes, receptor antagonists, receptor agonists, hormones, growth factors, small molecules, autogenous bone marrow, antibiotics, antimicrobial agents, antibodies, cytokines, bone morphogenic proteins, and growth factors.

244 . The method of claim 218 , wherein (i) is methylated collagen; (ii) is pentaerythritol tetrakis[mercaptoethyl poly(oxyethylene) ether]; and (iii) is pentaerythritol tetrakis [1-(1′-oxo-5-succimidylpentanoate)-2-poly(oxyethylene) ether].

245 . A method of repairing damaged cartilage tissue in a patient comprising:

(a) providing a flowable mixture comprising components (i), (ii), and (iii) or a partial reaction product of components (i), (ii), and (iii), wherein components (i), (ii), and (iii) are comprised of:

(i) a first hydrophilic polymer.

(ii) a crosslinkable component A having m nucleophilic groups, wherein m≧2, and

(iii) a crosslinkable component B having n electrophilic groups capable of reaction with the m nucleophilic groups to form covalent bonds;

(b) applying the flowable mixture to damaged cartilage tissue; and

(c) irrigating the applied mixture with an aqueous initiating buffer, to form a biocompatible, nonimmunogenic, crosslinked matrix,

wherein n≧2 and m+n>4, each of components A and B is biocompatible and nonimmunogenic, and at least one of components A and B is a second hydrophilic polymer.

246 . The method of claim 245 , wherein the reaction mixture is applied to the damaged cartilage tissue as a viscous liquid, partially polymerized gel, suspension, or spray.

247 . The method of claim 245 , wherein component A has the structural formula (I) and component B has the structural formula (II)

R 1 (-[Q 1 ] q -X) m   (I)

R 2 (-[Q 2 ] r -Y) n   (II)

wherein:

R 1 and R 2 are independently selected from the group consisting of C 2 to C 14 hydrocarbyl, heteroatom-containing C 2 to C 14 hydrocarbyl, hydrophilic polymers, and hydrophobic polymers;

X represents one of the m nucleophilic groups of component A;

Y represents one of the n electrophilic groups of component B;

Q 1 and Q 2 are linking groups; and

q and r are independently zero or 1.

248 . The method of claim 247 , wherein at least one of R 1 and R 2 is a synthetic hydrophilic polymer.

249 . The method of claim 245 , wherein the composition further comprises a third crosslinkable component C that is biocompatible and nonimmunogenic and has at least one functional group selected from the group consisting of:

(a) nucleophilic groups capable of reacting with the electrophilic groups of component B; and

(b) electrophilic groups capable of reacting with the nucleophilic groups of component A,

wherein the total number of functional groups on component C is represented by p, such that m+n+p>5.

250 . The method of claim 249 , wherein component C has the structural formula (III)

R 3 (-[Q 3 ] s -Fn) p   (III)

wherein:

R 3 is selected from the group consisting of C 2 to C 14 hydrocarbyl, heteroatom-containing C 2 to C 14 hydrocarbyl, hydrophilic polymers, and hydrophobic polymers;

Fn represents a functional group on component C; and

s is zero or 1.

251 . The method of claim 245 , wherein the nucleophilic groups on component A are selected from the group consisting of —NH 2 , —NHR 4 , —N(R 4 ) 2 , —SH, —OH, —COOH, —C 6 H 4 —OH, —PH 2 , —PHR 5 , —P(R 5 ) 2 , —NH—NH 2 , —CO—NH—NH 2 , and —C 5 H 4 N, wherein R 4 and R 5 are C 1 -C 12 hydrocarbyl.

252 . The method of claim 251 , wherein the nucleophilic groups are selected from —NH 2 and —NHR 4 where R 4 is lower hydrocarbyl.

253 . The method of claim 251 , wherein the electrophilic groups on component B are amino-reactive groups.

254 . The method of claim 253 , wherein the amino-reactive groups contain an electrophilically reactive carbonyl group susceptible to nucleophilic attack by a primary or secondary amine.

255 . The method of claim 218 , wherein the composition further comprises a biologically active agent that facilitates tissue healing and regeneration.

256 . The method of claim 255 , wherein the biologically active agent is selected from the group consisting of an angiogenesis inhibitor, paclitaxel, enzymes, receptor antagonists, receptor agonists, hormones, growth factors, small molecules, autogenous bone marrow, antibiotics, antimicrobial agents, antibodies, cytokines, bone morphogenic proteins, and growth factors.

257 . A method of repairing damaged soft tissues in a patient comprising placing into contact with the damaged soft tissues, a composition comprising components (i), (ii), and (iii) or a partial reaction product of components (i), (ii), and (iii), wherein components (i), (ii), and (iii) are comprised of:

(i) a first hydrophilic polymer;

(ii) a crosslinkable component A having m nucleophilic groups, wherein m≧2; and

(iii) a crosslinkable component B having n electrophilic groups capable of reaction with the m nucleophilic groups to form covalent bonds, wherein n>2 and m+n>4,

wherein each of components A and B is biocompatible and nonimmunogenic, at least one of the components A and B is a second hydrophilic polymer, and reaction of the components results in a biocompatible, nonimmunogenic, crosslinked matrix.

258 . The method of claim 257 , wherein the damaged soft tissue is connective tissue.

259 . The method of claim 257 , wherein the connective tissue is selected from the group consisting of articular ligaments, tendons, muscles, fat, or a soft tissue implant.

260 . The method of claim 259 , wherein the soft tissue implants are cosmetic implants.

261 . The method of claim 260 , wherein the cosmetic implants are breast implants or facial implants.

262 . The method of claim 257 , wherein the composition further comprises a biologically active agent.

263 . A kit for repairing damaged cartilage tissue, wherein the kit comprises:

(a) a first hydrophilic polymer;

(b) a crosslinkable component A having m nucleophilic groups, wherein m≧2; and

(c) a crosslinkable component B having n electrophilic groups capable of reaction with the m nucleophilic groups to form covalent bonds, wherein n≧2 and m+n>4,

wherein each of components A and B is biocompatible and nonimmunogenic, at least one of components A and B is a second hydrophilic polymer, and reaction of the components results in a biocompatible, nonimmunogenic, crosslinked matrix.

264 . The kit of claim 263 , wherein each of components A and B comprises polyalkeleneoxide.

265 . The kit of claim 263 , wherein the polyalkyleneoxide is a poly(ethylene oxide).

266 . The kit of claim 263 , wherein components A and B are the same.

267 . The kit of claim 263 , wherein components A and B are in admixture.

268 . The kit of claim 263 , wherein the admixture is in a solid form.

269 . The kit of claim 263 , further comprising a device for mixing (a), (b), and (c) and delivering (a), (b), and (c) or a partial reaction product thereof to the damaged cartilage tissue.

270 . The kit of claim 269 , wherein the device is configured to spray material onto a surface of the damaged cartilage tissue.

271 . The kit of claim 269 , wherein the device is configured to deliver material onto a surface of the damaged cartilage tissue as a liquid, gel, or suspension.

272 . The kit of claim 263 , wherein the first hydrophilic polymer is methylated collagen dissolved or suspended in aqueous solution of pH less than 7.

273 . The kit of claim 263 , further comprising (d), wherein (d) comprises an aqueous solution of pH greater than 7.

274 . The kit of claim 272 , wherein component A is (pentaerythritol tetrakis[mercaptoethyl poly(oxyethylene) ether] and component B is pentaerythritol tetrakis [1-(1′-oxo-5-succimidylpentanoate)-2-poly(oxyethylene) ether.